Takeda Pharmaceutical (TAK) Cash from Operations Growth (1y) (2019 - 2026)
Takeda Pharmaceutical (TAK) Cash from Operations Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.95 Bn | 88.09 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.88 Bn | 32.14 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.64 Bn | 30.70 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.04 Bn | 20.88 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.37 Bn | 18.57 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.45 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | 425.00% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 450.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.20% |
| Dec 31, 2025 | -3.92% |
| Sep 30, 2025 | 36.28% |
| Jun 30, 2025 | 36.09% |
| Mar 31, 2025 | -22.54% |
| Dec 31, 2024 | 154.78% |
| Sep 30, 2024 | 36.76% |
| Jun 30, 2024 | 62.26% |
| Mar 31, 2024 | -15.33% |
| Dec 31, 2023 | -62.99% |
| Sep 30, 2023 | -13.92% |
| Jun 30, 2023 | 3.51% |
| Mar 31, 2023 | -31.30% |
| Dec 31, 2022 | -12.43% |
| Sep 30, 2022 | -24.45% |
| Jun 30, 2022 | -57.27% |
| Mar 31, 2022 | -14.68% |
| Dec 31, 2021 | 46.56% |
| Sep 30, 2021 | -8.64% |
| Jun 30, 2021 | 12.39% |